Re-Stem Biotech to hold Grand Opening of New Location and Expansion of its Corporate Office and R&D Facility
SUZHOU, China - May 15, 2019 - PRLog -- Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis, spinal cord injury and cancer, today announced a Grand Opening ceremony to mark the relocation and expansion of its corporate office and main research and development facility in Suzhou, China on May 18, 2019. The state-of-the-
Date: Saturday, May 18, 2019
Time: 10:30 am – 12:00 pm
Location: 1463 Wuzhong Avenue, Building A1, Suzhou, Jiangsu Province, China
To register to attend this event, or for media enquiries, please contact judyanna.chen@
About Re-Stem Biotech
Re-Stem Biotech (Re-Stem) is a biotechnology firm engaged in the research and development of cell based therapies and products. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and management team, Re-Stem currently has a robust technology platform including three profitable therapies on the market and eight other therapies and products in the pipeline. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing and Ganzhou.
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as "will," "may," "expects," "plans," "intends," "estimates,"